Chiome Bioscience Corrects FY2025 Results as Losses and Cash Burn Persist

Chiome Bioscience Inc. ( (JP:4583) ) has provided an announcement.

Chiome Bioscience has issued an updated version of its non-consolidated financial results for the fiscal year ended December 31, 2025, correcting specific items related to share count, cash flow statements, segment information, and per-share data. The company reported a 24% year-on-year decline in net sales to ¥593 million and a net loss of ¥982 million, with equity and cash balances shrinking significantly, underscoring continued financial pressure and the importance of upcoming shareholder and investor briefings.

Total assets fell to ¥1,727 million and equity ratio dropped to 64.1%, while cash and cash equivalents decreased to ¥1,205 million despite positive financing cash flows, indicating reliance on external funding amid persistent operating cash outflows. Although the losses narrowed slightly compared with the previous year, the sustained negative earnings and erosion of net assets highlight ongoing profitability challenges that stakeholders will closely monitor as Chiome navigates its growth-stage biotech strategy.

The most recent analyst rating on (JP:4583) stock is a Hold with a Yen100.00 price target. To see the full list of analyst forecasts on Chiome Bioscience Inc. stock, see the JP:4583 Stock Forecast page.

More about Chiome Bioscience Inc.

Chiome Bioscience Inc. is a Japan-based biotechnology company listed on the Tokyo Stock Exchange Growth market, focused on drug discovery using antibody technologies. The company generates revenue primarily through research alliances and licensing in the life sciences sector, serving pharmaceutical and biotechnology partners seeking novel therapeutic candidates.

Average Trading Volume: 730,470

Technical Sentiment Signal: Sell

Current Market Cap: Yen7.37B

For detailed information about 4583 stock, go to TipRanks’ Stock Analysis page.